Progenics Pharmaceuticals Competitors and Similar CompaniesClear all
Progenics Pharmaceuticals's competitors and similar companies include Aura Biosciences, NuCana, TRON and Xynomic Pharmaceuticals.
 Progenics Pharmaceuticals Progenics Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for cancer patients. |  Aura Biosciences ura Biosciences is a clinical-stage biotechnology company that designs an oncology platform for the delivery of drugs targeting cancer indications, focusing on ocular and urologic oncology. |  NuCana NuCana is a clinical-stage biopharmaceutical company developing new medicines to treat cancer. |  TRON TRON Mainz is a biopharmaceutical research organization that offers diagnostics and drugs for the treatment of cancer and other severe diseases. |  Xynomic Pharmaceuticals Xynomic Pharmaceuticals is a clinical-stage oncology therapeutics biopharmaceutical company developing oncology drugs. | |
Founding Date | Founding Date 1986 | Founding Date 2009 | Founding Date 2008 | Founding Date 2010 | Founding Date 2016 |
Type | Type Subsidiary | Type Public | Type Public | Type Private | Type Public |
Tags | |||||
Locations | Locations New York, US HQ Billerica, US | Locations Cambridge, US HQ | Locations Edinburgh, GB HQ London, GB Newton, US | Locations Mainz, DE HQ | Locations Dover, US HQ Poway, US |
Employees | Employees 52 | Employees 42 | Employees 25 | Employees 1505% increase | Employees 25 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 378.5 m | Valuation ($) 17.4 m | Valuation ($) N/A | Valuation ($) 102.7 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $35m (FY, 2019) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods $3.2m (FY, 2019) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $31.8m (FY, 2019) | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit N/A |
Net income | Net income ($68.6m) (FY, 2019) | Net income ($76.4m) (FY, 2023) | Net income (£27.6m) (FY, 2023) | Net income N/A | Net income ($25.1m) (FY, 2019) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 213.9m | Total funding raised $ 67.5m | Total funding raised N/A | Total funding raised $ 4.8m |
For sources of this data, please see the company profile
View Company Profiles
Aura Biosciences
HQ
Cambridge, US
Employees
42
ura Biosciences is a clinical-stage biotechnology company that designs an oncology platform for the delivery of drugs targeting cancer indications, focusing on ocular and urologic oncology.
View companyNuCana
HQ
Edinburgh, GB
Employees
25
NuCana is a clinical-stage biopharmaceutical company developing new medicines to treat cancer.
View companyTRON
HQ
Mainz, DE
Employees
150↑ 5% increase
TRON Mainz is a biopharmaceutical research organization that offers diagnostics and drugs for the treatment of cancer and other severe diseases.
View companyXynomic Pharmaceuticals
HQ
Dover, US
Employees
25
Xynomic Pharmaceuticals is a clinical-stage oncology therapeutics biopharmaceutical company developing oncology drugs.
View company